Ustekinumabitutkimus lapsilla, joilla on kohtalaisen tai vaikeasti aktiivinen Crohnin tauti (UNITI Jr)
Kolmannen vaiheen tutkimus ustekinumabin tehosta, turvallisuudesta ja farmakokinetiikasta avoimena laskimonsisäisenä induktiohoitona, jota seuraa satunnaistettu kaksoissokkoutettu ihonalainen ustekinumabihoito potilailla, joilla on kohtalaisen tai vaikeasti aktiivinen Crohnin tauti
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Todellinen)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Study Contact
- Puhelinnumero: 844-434-4210
- Sähköposti: Participate-In-This-Study@its.jnj.com
Opiskelupaikat
-
-
-
Brussels, Belgia, 1200
- Cliniques Universitaires Saint Luc
-
Brussels, Belgia, 1020
- Universitair Kinderziekenhuis Koningin Fabiola
-
Ghent, Belgia, 9000
- UZ Gent
-
Jette, Belgia, 1090
- UZ Brussel
-
Leuven, Belgia, 3000
- UZ Leuven
-
-
-
-
-
Be’er Ya‘aqov, Israel, 70300
- Yitzhak Shamir Medical Center
-
Haifa, Israel, 34362
- Carmel Medical Center
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
Petah Tikva, Israel, 4920235
- Schneider Children's Medical Center
-
-
-
-
-
Bunkyō City, Japani, 113 8431
- Juntendo University Hospital
-
Gunma, Japani, 371-0034
- Gunma University Hospital
-
Ikoma, Japani, 630-0293
- Kindai University Nara Hospital
-
Kurume, Japani, 830-0011
- Kurume University Hospital
-
Saitama Shi, Japani, 330-8777
- Saitama Childrens Medical Center
-
Sendai, Japani, 989-3126
- Miyagi Children's Hospital
-
Setagaya Ku, Japani, 157 8535
- National Center for Child Health and Development
-
Shimotsuke, Japani, 329-0498
- Jichi Medical University Hospital
-
Tsu, Japani, 514 8507
- Mie University Hospital
-
-
-
-
-
Gdansk, Puola, 80 803
- Szpital im. M. Kopernika
-
Krakow, Puola, 30 663
- Uniwersytecki Szpital Dzieciecy w Krakowie
-
Rzeszów, Puola, 35-302
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, Puola, 04 501
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Puola, 04 730
- Instytut Pomnik Centrum Zdrowia Dziecka
-
-
-
-
-
Aachen, Saksa, 52074
- Universitätsklinikum Aachen
-
Berlin, Saksa, 13353
- Charite-Universitätsmedizin Berlin - Berlin
-
Essen, Saksa, 45147
- Universitätsklinikum Essen
-
Hanover, Saksa, 30625
- Medizinische Hochschule Hannover
-
Munich, Saksa, 80337
- Dr. von Haunersches Kinderspital
-
Regensburg, Saksa, 93049
- KUNO Klinik St. Hedwig
-
Ulm, Saksa, 89075
- Universitätsklinikum Ulm
-
-
-
-
-
Budapest, Unkari, 1083
- Semmelweis Egyetem
-
Debrecen, Unkari, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Miskolc, Unkari, 3526
- Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
-
Nyíregyháza, Unkari, 4400
- Szabolcs Szatmár Bereg Vármegyei Oktatókórház
-
Szeged, Unkari, 6720
- Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
-
-
-
-
-
Kazan', Venäjä, 420138
- Kazan State Medical University
-
Moscow, Venäjä, 119571
- Russian National Research Medical University named after N.I.Pirogov
-
Nizhny Novgorod, Venäjä, 603950
- Privolzhsky Research Medical University of Ministry of Health of Russian Federation
-
Yaroslavl, Venäjä, 150032
- Yaroslavl Regional Children's Clinical Hospital
-
-
-
-
-
Birmingham, Yhdistynyt kuningaskunta, B4 6NH
- Birmingham Children's Hospital
-
Bristol, Yhdistynyt kuningaskunta, BS2 8BJ
- University Hospitals Bristol and Weston NHS Foundation Trust
-
Cambridge, Yhdistynyt kuningaskunta, CB2 0QQ
- Cambridge University Hospitals NHS Foundation Trust
-
Edinburgh, Yhdistynyt kuningaskunta, EH16 4TJ
- Royal Hospital for Children and Young People
-
London, Yhdistynyt kuningaskunta, E1 2AT
- Royal London Hospital
-
-
-
-
Delaware
-
Wilmington, Delaware, Yhdysvallat, 19803
- Nemours DuPont Hospital for Children
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30342
- Children's Center for Digestive Health Care
-
-
Minnesota
-
Rochester, Minnesota, Yhdysvallat, 55905
- Mayo Clinic
-
-
New Jersey
-
Morristown, New Jersey, Yhdysvallat, 07962
- Morristown Memorial Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Yhdysvallat, 28207
- Levine Childrens at Atrium Health
-
-
Ohio
-
Cleveland, Ohio, Yhdysvallat, 44106
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Yhdysvallat, 17033
- Penn State Hershey Children's Hospital
-
-
Texas
-
Fort Worth, Texas, Yhdysvallat, 76104
- Cook Childrens Medical Center
-
-
Virginia
-
Fairfax, Virginia, Yhdysvallat, 22031
- Pediatric Specialists Of Virginia
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Sisällyttämiskriteerit:
- sinulla on Crohnin tauti tai fistuloiva Crohnin tauti, johon liittyy aktiivinen paksusuolentulehdus, ileiitti tai ileokoliitti, joka on vahvistettu milloin tahansa endoskopialla ja histologialla
- Sinulla on oltava kohtalaisen tai vaikeasti aktiivinen Crohnin tauti (perustason lasten Crohnin taudin aktiivisuusindeksin [PCDAI] pistemäärä on suurempi kuin [>] 30); saada ileokolonoskopia, jossa on näyttöä aktiivisesta Crohnin taudista, joka määritellään haavaumiksi (joka on yhtä suuri kuin Crohnin taudin yksinkertainen endoskooppinen pistemäärä [SES-CD], joka on suurempi tai yhtä suuri kuin [>=] 3) tämän tutkimuksen seulonnan aikana. Ileokolonoskopiatoimenpiteen on tapahduttava noin 3 viikon sisällä ennen tutkimustoimenpiteen antamista viikolla 0 (induktiojakso). Videoileokolonoskopiaa, joka on tallennettu 3 kuukauden sisällä ennen viikon 0 (Induktiojakso) käyntiä, voidaan käyttää, jos seulontaan osallistuja, jolle tehtiin ileokolonoskopia, mutta joka ei muusta syystä läpäissyt alkuseulontaa, tapauskohtaisesti sen jälkeen, kun neuvotella sponsorin kanssa. Jos haavaumia ei voida arvioida ahtautumisen tai riittämättömän suolen valmistelun vuoksi, sen sijaan voidaan soveltaa vähintään yhtä seuraavista kriteereistä: epänormaali C-reaktiivinen proteiini (CRP) (> 0,3 milligrammaa desilitraa kohti [mg/dl] tai 3,0 milligrammaa litrassa [mg/l] seulonnassa) tai; ulosteen kalprotektiini >= 250 mg/kg [mg/kg] tai >= 250 mikrogrammaa/gramma [mcg/g] seulonnassa
- Jos saa enteraalista ravintoa, hänen on täytynyt olla vakaassa hoito-ohjelmassa vähintään 2 viikkoa ennen induktioviikkoa 0 (viikko I-0)
- Hedelmällisessä iässä olevilla naisilla on oltava negatiivinen erittäin herkkä virtsaraskaustesti seulonnassa ja viikolla I-0 ennen tutkimusinterventiota
Poissulkemiskriteerit:
- hänellä on Crohnin taudin komplikaatioita, kuten oireenmukaisia ahtaumaa tai ahtaumaa, lyhytsuolen oireyhtymää tai mikä tahansa muu ilmentymä, jonka odotetaan vaativan leikkausta ja jotka voivat estää PCDAI:n käytön hoitovasteen arvioinnissa tai mahdollisesti häiritsevät kykyä arvioida ustekinumabihoidon vaikutusta
- sinulla on ollut piilevä tai aktiivinen granulomatoottinen infektio, histoplasmoosi tai kokkidioidomykoosi tai sinulla on ollut ei-tuberkuloottinen mykobakteeri-infektio ennen seulontaa
- Mikä tahansa pahanlaatuinen kasvain, mukaan lukien lymfoproliferatiivinen sairaus, mukaan lukien lymfooma, tai merkit ja oireet, jotka viittaavat mahdolliseen lymfoproliferatiiviseen sairauteen, kuten epätavallisen kokoinen tai epätavallisen sijainnin lymfadenopatia (esimerkiksi kaulan takakolmion solmut, infraclavicular, epitrochlear, tai periaortan alueet) ja monoklonaalinen gammopatia, jolla on määrittelemätön merkitys, tai kliinisesti merkittävä hepatomegalia tai splenomegalia
- sinulla on ollut kohtalainen tai vaikea etenevä tai hallitsematon maksan tai munuaisten vajaatoiminta; tai merkittäviä sydän-, verisuoni-, keuhko-, maha-suolikanavan, endokriinisiä, neurologisia, hematologisia, psykiatrisia (mukaan lukien itsetuhoisuus) tai aineenvaihduntahäiriöitä
- saanut tutkimustoimenpiteen, mukaan lukien kaikki tutkittavat rokotteet, tai käyttänyt invasiivista lääketieteellistä tutkimuslaitetta 3 kuukauden sisällä ennen suunniteltua ensimmäistä tutkimusannosta tai on tällä hetkellä mukana tutkimustutkimuksessa; tutkimusrokotteen saaminen koronavirustautia 2019 (COVID-19) varten ei ole automaattinen poissulkemiskriteeri
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Avoin ustekinumabi suonensisäinen (IV): Induktiojakso
Kaikki osallistujat saavat yhden IV-annoksen ustekinumabia induktioviikolla 0 (I-0) kehon pinta-alan (BSA) (milligrammaa neliömetriä kohti [mg/m^2]) tai paino-porrastetun induktioannoksen (milligrammaa kilogrammaa kohti) perusteella. [mg/kg]).
|
Ustekinumabi annetaan suonensisäisesti induktiojakson aikana ja ihon alle ylläpitojakson aikana.
|
|
Kokeellinen: Ustekinumabi ihonalainen (SC) 8 viikon välein (q8w): Huoltojakso
Osallistujat saavat ustekinumabia ihonalaisesti q8w BSA:n (mg/m^2) tai paino-porrastetun induktioannoksen (mg/kg) perusteella ylläpitoviikkoina (viikot M) -0, M-8, M-16, M-24 , M 32 ja M-40 sekä vastaava lumelääke viikoilla M-12 ja M-36 sokeiden ylläpitämiseksi.
|
Ustekinumabi annetaan suonensisäisesti induktiojakson aikana ja ihon alle ylläpitojakson aikana.
Vastaava lumelääke annetaan SC-injektiona.
|
|
Kokeellinen: Ustekinumab SC 12 viikon välein (q12w): Huoltojakso
Osallistujat saavat ihonalaista ustekinumabia q12w BSA:n (mg/m^2) tai painoporrastetun induktioannoksen (mg/kg) perusteella viikoilla M-0, M-12, M-24, M-36 ja vastaavaa lumelääkettä klo. Viikot M-8, M-16, M-32 ja M-40 sokeiden ylläpitämiseksi.
|
Ustekinumabi annetaan suonensisäisesti induktiojakson aikana ja ihon alle ylläpitojakson aikana.
Vastaava lumelääke annetaan SC-injektiona.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Aikaikkuna: Induction Week 8 (Week I-8)
|
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations.
The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score =5.
For albumin level, the maximum score = 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Induction Week 8 (Week I-8)
|
|
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Aikaikkuna: Maintenance Week 44 (Study Week 52)
|
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Aikaikkuna: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with TEAEs were reported.
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Aikaikkuna: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with TESAEs was reported.
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly.
TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Aikaikkuna: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
|
Number of participants with AEs leading to discontinuation of study intervention were reported.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
|
|
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Aikaikkuna: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Aikaikkuna: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported.
It included hemoglobin (Hb).
Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences.
Higher grades showed more severe abnormalities.
Only abnormalities where atleast one participant had data are reported.
Inc = increased, Dec= decreased.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Aikaikkuna: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with abnormalities in clinical laboratory parameters were reported.
It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB).
Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences.
Higher grades showed more severe abnormalities.
Only abnormalities where at least one participant had data are reported.
Inc = increased, Dec= decreased.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Aikaikkuna: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Aikaikkuna: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
|
Serum ustekinumab concentrations were reported.
|
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Aikaikkuna: Induction Week 6 (Week I-6)
|
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10.
The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations.
Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity.
Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90.
Higher score indicate greater severity.
The sPCDAI score was calculated only when >=3 of the 6 components were available.
|
Induction Week 6 (Week I-6)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Aikaikkuna: Induction Week 8
|
Assessment of response in children with Crohn's disease was evaluated using the PCDAI.
Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations.
Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality).
For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
|
Induction Week 8
|
|
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Aikaikkuna: Induction Week 6
|
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10.
The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations.
Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity.
Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90.
Higher score indicate greater severity.
The sPCDAI score was only calculated when >=3 of the 6 components were available.
|
Induction Week 6
|
|
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Aikaikkuna: Maintenance Period Week 8 (Study Week 16)
|
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing.
Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum.
Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity.
Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
|
Maintenance Period Week 8 (Study Week 16)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Aikaikkuna: Maintenance Week 8 (Study Week 16)
|
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations.
Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality).
For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10.
Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
|
Maintenance Week 8 (Study Week 16)
|
|
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Aikaikkuna: Maintenance Week 44 (Study Week 52)
|
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing.
Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum.
Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity.
Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
|
Maintenance Week 44 (Study Week 52)
|
|
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Aikaikkuna: Maintenance Week 44 (Study Week 52)
|
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations.
Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality).
For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10.
Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
|
Maintenance Week 44 (Study Week 52)
|
|
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Aikaikkuna: Maintenance Period Week 44 (Study Week 52)
|
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Period Week 44 (Study Week 52)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Aikaikkuna: Maintenance Week 44 (Study Week 52)
|
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Week 44 (Study Week 52)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Opintojohtaja: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Todellinen)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Suoliston sairaudet
- Ruoansulatuskanavan sairaudet
- Ruoansulatuskanavan sairaudet
- Gastroenteriitti
- Tulehdukselliset suolistosairaudet
- Crohnin tauti
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Vasta -aineet, monoklonaalinen, humanisoitu
- Vasta -aineet, monoklonaalinen
- Vasta -aineet
- Immunoglobuliinit
- Immunoproteiinit
- Veriproteiinit
- Seerumin globuliinit
- Globuliinit
- Ustekinumabi
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- CR108864
- 2019-004225-24 (EudraCT-numero)
- CNTO1275CRD3004 (Muu tunniste: Janssen Research & Development, LLC)
- 2023-504978-38-00 (Rekisterin tunniste: EUCT number)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .